PMID- 24794284
OWN - NLM
STAT- MEDLINE
DCOM- 20141014
LR  - 20220316
IS  - 1879-1891 (Electronic)
IS  - 0002-9394 (Linking)
VI  - 158
IP  - 2
DP  - 2014 Aug
TI  - Gray hyper-reflective subretinal exudative lesions in exudative age-related 
      macular degeneration.
PG  - 354-61
LID - S0002-9394(14)00228-1 [pii]
LID - 10.1016/j.ajo.2014.04.025 [doi]
AB  - PURPOSE: To investigate the effects of ranibizumab 0.5 mg on gray 
      hyper-reflective subretinal lesions diagnosed by spectral-domain optical 
      coherence tomography (SD OCT) in patients with exudative age-related macular 
      degeneration (AMD). DESIGN: Retrospective interventional study. METHODS: Data 
      from 28 consecutive patients affected with neovascular AMD that presented 
      subretinal hyper-reflective lesions as visualized by SD OCT were collected. Gray 
      hyper-reflective subretinal lesion characteristics were analyzed before and after 
      intravitreal ranibizumab 0.5 mg injection. RESULTS: Thirty eyes of 28 patients (5 
      male, 23 female, aged 57-91 years) were included. At study entry, gray lesion was 
      associated with exudative features in 24 of 30 eyes (80%), including subretinal 
      fluid (SRF) in 20 of 30 eyes (67%) and retinal cystoid spaces in 11 of 30 eyes 
      (37%). Twenty-four eyes with exudative features at study entry received prompt 
      treatment; 6 eyes without exudative features at study entry received deferred 
      treatment (after 1 month observation), when exudative signs emerged (SRF in 3/6 
      eyes and retinal cystoid spaces in 5/6 eyes). Ninety-three percent of the gray 
      lesions responded to ranibizumab treatment at 2 months and 77% at 6 months. Gray 
      hyper-reflective subretinal lesion thickness was significantly reduced after 
      treatment at both 2 months (from 482+/-116 mum to 367+/-102 mum, P<.0001) and 6 months 
      (from 482+/-116 mum to 369+/-71 mum, P<.0001). CONCLUSION: Our findings suggest that 
      gray hyper-reflective subretinal lesions might be considered as a qualitative 
      criterion for retreatment of exudative AMD. They may represent an early sign of 
      active choroidal neovascularization, and should prompt to early treatment.
CI  - Copyright (c) 2014 Elsevier Inc. All rights reserved.
FAU - Ores, Raphaelle
AU  - Ores R
AD  - Department of Ophthalmology, Centre Hospitalier Intercommunal de Creteil, 
      Universite Paris Est, Creteil, France.
FAU - Puche, Nathalie
AU  - Puche N
AD  - Department of Ophthalmology, Centre Hospitalier Intercommunal de Creteil, 
      Universite Paris Est, Creteil, France.
FAU - Querques, Giuseppe
AU  - Querques G
AD  - Department of Ophthalmology, Centre Hospitalier Intercommunal de Creteil, 
      Universite Paris Est, Creteil, France.
FAU - Blanco-Garavito, Rocio
AU  - Blanco-Garavito R
AD  - Department of Ophthalmology, Centre Hospitalier Intercommunal de Creteil, 
      Universite Paris Est, Creteil, France.
FAU - Merle, Benedicte
AU  - Merle B
AD  - Department of Ophthalmology, Centre Hospitalier Intercommunal de Creteil, 
      Universite Paris Est, Creteil, France.
FAU - Coscas, Gabriel
AU  - Coscas G
AD  - Department of Ophthalmology, Centre Hospitalier Intercommunal de Creteil, 
      Universite Paris Est, Creteil, France.
FAU - Oubraham, Hassiba
AU  - Oubraham H
AD  - Department of Ophthalmology, Centre Hospitalier Intercommunal de Creteil, 
      Universite Paris Est, Creteil, France.
FAU - Semoun, Oudy
AU  - Semoun O
AD  - Department of Ophthalmology, Centre Hospitalier Intercommunal de Creteil, 
      Universite Paris Est, Creteil, France.
FAU - Souied, Eric H
AU  - Souied EH
AD  - Department of Ophthalmology, Centre Hospitalier Intercommunal de Creteil, 
      Universite Paris Est, Creteil, France. Electronic address: 
      eric.souied@chicreteil.fr.
LA  - eng
PT  - Journal Article
DEP - 20140502
PL  - United States
TA  - Am J Ophthalmol
JT  - American journal of ophthalmology
JID - 0370500
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - ZL1R02VT79 (Ranibizumab)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Antibodies, Monoclonal, Humanized/*administration & dosage
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Fluorescein Angiography
MH  - Follow-Up Studies
MH  - Fundus Oculi
MH  - Humans
MH  - Intravitreal Injections
MH  - Male
MH  - Middle Aged
MH  - Ranibizumab
MH  - Retina/drug effects/*pathology
MH  - Retrospective Studies
MH  - Subretinal Fluid/*drug effects
MH  - Tomography, Optical Coherence/*methods
MH  - Treatment Outcome
MH  - Visual Acuity
MH  - Wet Macular Degeneration/*diagnosis/drug therapy
EDAT- 2014/05/06 06:00
MHDA- 2014/10/15 06:00
CRDT- 2014/05/06 06:00
PHST- 2013/10/12 00:00 [received]
PHST- 2014/04/24 00:00 [revised]
PHST- 2014/04/25 00:00 [accepted]
PHST- 2014/05/06 06:00 [entrez]
PHST- 2014/05/06 06:00 [pubmed]
PHST- 2014/10/15 06:00 [medline]
AID - S0002-9394(14)00228-1 [pii]
AID - 10.1016/j.ajo.2014.04.025 [doi]
PST - ppublish
SO  - Am J Ophthalmol. 2014 Aug;158(2):354-61. doi: 10.1016/j.ajo.2014.04.025. Epub 
      2014 May 2.